Pathobiomes in Gut of Critically Ill Patients
Launched by UNIVERSITY OF CHICAGO · Feb 11, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Pathobiomes in Gut of Critically Ill Patients," is investigating how a specific bacteria called Pseudomonas aeruginosa affects critically ill surgical patients. Even with strong antibiotics, about half of these patients have this bacteria in their intestines, which can lead to serious complications and even death. The study aims to understand why this happens and how the bacteria can become more harmful when a patient's health is declining. Researchers will collect stool samples from patients to see how these samples influence the bacteria's ability to cause illness.
To participate in this trial, individuals must be between 18 and 85 years old, regardless of their ethnicity. Unfortunately, those with a known history of HIV/AIDS, who are currently pregnant, or are incarcerated cannot take part. Participants can expect to provide stool samples, which will be analyzed to better understand the relationship between their gut health and the behavior of Pseudomonas aeruginosa. This research could help improve care for critically ill patients and potentially lead to better treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any ethnicity
- • Age \> 18 years and \< 85 years
- Exclusion Criteria:
- • A known history of HIV/AIDS
- • Active pregnancy
- • Are incarcerated will be excluded from the study.
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hyde Park, Illinois, United States
Patients applied
Trial Officials
John Alverdy, MD FACS FSIS
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported